CO5680440A2 - COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED - Google Patents

COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED

Info

Publication number
CO5680440A2
CO5680440A2 CO05003060A CO05003060A CO5680440A2 CO 5680440 A2 CO5680440 A2 CO 5680440A2 CO 05003060 A CO05003060 A CO 05003060A CO 05003060 A CO05003060 A CO 05003060A CO 5680440 A2 CO5680440 A2 CO 5680440A2
Authority
CO
Colombia
Prior art keywords
disorder
disorders
serotonin reuptake
anxiety
pharmaceutical composition
Prior art date
Application number
CO05003060A
Other languages
Spanish (es)
Inventor
Arne Mork
Ivo Franciscus Hubert Cremers Thomas
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO5680440A2 publication Critical patent/CO5680440A2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Uso de un compuesto, que es un inhibidor de recaptación de serotonina, y otro compuesto, que es un antagonista del receptor GABAB, agonista inverso o agonista parcial, para la preparación de una composición farmacéutica para el tratamiento de la depresión, trastornos de ansiedad y otros trastornos afectivos, tales como trastorno de ansiedad generalizada, pánico/ansiedad, trastorno obsesivo compulsivo, trastorno de estrés agudo, trastorno de estrés postraumático y trastorno de ansiedad social, trastornos alimentarios tales como bulimia, anorexia y obesidad, fobias, distimia, síndrome premenstrual, trastornos cognitivos, trastornos de control del impulso, trastorno de déficit de atención/hiperactividad, abuso de fármacos o cualquier otro trastorno que responda a inhibidores de recaptación de serotonina.2.- Uso de un antagonista del receptor GABAB, agonista inverso o agonista parcial, para la preparación de una composición farmacéutica para utilizarse en combinación con un inhibidor de recaptación de serotonina.3.- Uso de un antagonista del receptor GABAB, agonista inverso o agonista parcial, para la preparación de una composición farmacéutica útil para aumentar y/o proveer un comienzo más rápido del efecto terapéutico de un inhibidor de recaptación de serotonina.1.- Use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABAB receptor antagonist, inverse agonist or partial agonist, for the preparation of a pharmaceutical composition for the treatment of depression, disorders of anxiety and other affective disorders, such as generalized anxiety disorder, panic / anxiety, obsessive compulsive disorder, acute stress disorder, post-traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia , premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit / hyperactivity disorder, drug abuse or any other disorder that responds to serotonin reuptake inhibitors.2.- Use of a GABAB receptor antagonist, inverse agonist or partial agonist, for the preparation of a pharmaceutical composition for use in combination with a serotonin reuptake inhibitor. 3.- Use of a GABAB receptor antagonist, inverse agonist or partial agonist, for the preparation of a pharmaceutical composition useful for increasing and / or providing a faster onset of the therapeutic effect of an inhibitor of serotonin reuptake.

CO05003060A 2002-06-20 2005-01-17 COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED CO5680440A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200943 2002-06-20

Publications (1)

Publication Number Publication Date
CO5680440A2 true CO5680440A2 (en) 2006-09-29

Family

ID=36701304

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05003060A CO5680440A2 (en) 2002-06-20 2005-01-17 COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED

Country Status (8)

Country Link
CN (1) CN101358379A (en)
AR (1) AR039723A1 (en)
CO (1) CO5680440A2 (en)
EA (1) EA200401468A1 (en)
IS (1) IS2444B (en)
SI (1) SI1545552T1 (en)
UA (1) UA81248C2 (en)
ZA (1) ZA200409278B (en)

Also Published As

Publication number Publication date
AR039723A1 (en) 2005-03-09
IS2444B (en) 2008-11-15
CN101358379A (en) 2009-02-04
ZA200409278B (en) 2006-04-26
EA200401468A1 (en) 2005-04-28
UA81248C2 (en) 2007-12-25
SI1545552T1 (en) 2007-08-31
IS7557A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
CY1124111T1 (en) GLUTAMATE REGULATORS IN THE TREATMENT OF MENTAL DISORDERS
CL2008002916A1 (en) Compounds derived from triazolopyridine, 11-beta-hydroxysteroid dehydrogenase type I inhibitors; pharmaceutical composition comprising them; and its use in the treatment and / or prevention of diabetes, dyslipidemia, obesity, among others.
NO20055208L (en) 4- (2-Phenylsulfanyl-phenyl) -piperidine derivatives as serotonin reuptake inhibitors
CL2007003065A1 (en) Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others
CO6640335A2 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity or prediabetes
DE60200492D1 (en) Combination of an inhibitor of serotonin reuptake and an atypical antipsychotic for the treatment of depression, obsessive compulsive disorder and psychosis
ECSP055885A (en) CARBOSTIRILE DERIVATIVES AND INHIBITORS OF SEROTONINE RECAPTATION THAT SERVE FOR THE TREATMENT OF HUMOR DISORDERS
AR033308A1 (en) USE OF ENANTIOMERICALLY PURE SCITALOPRAM
MX2023013040A (en) Compositions and methods for the treatment of depression.
RU2012152922A (en) TREATMENT OF PSYCHOLOGICAL CONDITIONS WITH THE USE OF M1-MUSCARINE RECEPTOR ANTAGONISTS
JP2007513052A5 (en)
DK1545552T3 (en) Combination therapy using a serotin reuptake inhibitor
RU2007140986A (en) PREVENTIVE OR THERAPEUTIC AGENT AGAINST DEPRESSION OR ANXIETY DISORDER
NO20061167L (en) The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
CO5680440A2 (en) COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED
AR047715A1 (en) ANALEPTIC AND ANTDEPRESSIVE COMBINATIONS
AR048134A1 (en) THE COMBINATION OF AN INHIBITOR OF THE RECOVERY OF SEROTONINE AND AN ANTAGONIST OF THE RECEIVER OF HISTAMINE 3, THE INVESTED AGONIST OR THE PARTIAL AGONIST
AR047716A1 (en) ANALEPTIC AND ANTIDEPRESSIVE COMBINATIONS
CO5680458A2 (en) THE COMBINATION OF A SEROTONINE REABSORTION INHIBITOR AND A TYPE 1 GLICINE TRANSPORTER INHIBITOR FOR DEPRESSION TREATMENT
AR045314A1 (en) PHARMACEUTICAL COMPOSITIONS OF ANALEPTICS AND ANTIDEPRESSANTS
BRPI0415899A (en) uses of a compound, and an h3 receptor antagonist, inverse agonist or partial agonist, pharmaceutical composition, method for identifying compounds useful for treating disease, and compound
BR0314431A (en) Antidepressant piperidine derivatives of heterocyl-fused benzodioxanes
AR056056A1 (en) ASSOCIATION BETWEEN AGOMELATIN AND AN INHIBITOR OF THE RECOVERY OF NORADRENALINE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
RU2009101143A (en) TREATMENT OF PSYCHOLOGICAL CONDITIONS WITH THE APPLICATION OF ANTAGGONISTS OF M1-MUSCARINE RECEPTORS
EA201070736A1 (en) 4- [2,3-DIFFOR-6- (2-Fluoro-4-Methylphenylsulfanyl) phenyl] piperidine